dabogratinib

Carlsbad, Calif. – September 12, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will hold a virtual fireside chat and one-on-one investor meetings at the Cantor Global Healthcare Conference 2026 on Wednesday, September 9, 2026 at 1:00 PM ET.

Clinical-stage biotech to address investors from New York event

The presentation, though based in New York, NY, will be conducted virtually, with a live webcast accessible via the "For Investors" section of Tyra's website. A replay will be made available following the session.

Carlsbad – September 08, 2026 -- Tyra Biosciences, Inc. (Nasdaq: TYRA) will disclose initial clinical results from its SURF302 Phase 2 study of oral dabogratinib in intermediate risk non-muscle invasive bladder cancer (IR NMIBC) during a conference call scheduled for September 9, 2026, at 8:00 am ET.

Tyra sets September 9 call to unveil first SURF302 data

The clinical-stage biotech confirmed the call and webcast will present initial efficacy and safety data from the ongoing SURF302 trial, marking the first public disclosure of results for dabogratinib in this bladder cancer indication.

Dabogratinib targets FGFR3-driven tumors as lead pipeline asset

Dabogratinib is Tyra's lead precision medicine candidate, developed as a potential first-in-class selective FGFR3 inhibitor. Beyond IR NMIBC, the company is advancing the drug for low-grade upper tract urothelial cancer (LG-UTUC) and achondroplasia (ACH).